Milciclib Gemcitabine Combination Therapy KRAS Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for effective treatments for KRAS mutated cancers, particularly in KRAS G12C driven non-small cell lung cancer, where current therapies show poor outcomes and resistance to gemcitabine is common.
Innovation Solution
The combination of milciclib, a cyclin-dependent kinase (CDK) inhibitor, with a DNA damaging agent such as gemcitabine, topotecan, or irinotecan, to target and inhibit KRAS mutant tumors, reversing resistance and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gemcitabine is used as monotherapy for KRAS mutated cancers, then treatment is simple and well-tolerated, but treatment efficacy is poor and resistance develops
Solution Approach 1:
The patent combines milciclib (a CDK inhibitor) with gemcitabine (a DNA damaging agent) into a combination therapy regimen. This merging of two different mechanisms of action addresses the resistance and poor efficacy issues of gemcitabine monotherapy while maintaining relative treatment simplicity through established administration protocols
2Reliability
If combination therapy with milciclib and DNA damaging agent is used, then treatment efficacy is improved and resistance is reversed, but treatment complexity increases
Solution Approach 1:
The combination therapy is segmented into distinct components with specific dosing schedules: milciclib administered at 150mg/day and DNA damaging agents at established doses. This segmentation allows for systematic management of the complex regimen, enabling clinicians to address each component separately while achieving synergistic anti-tumorigenic effects
3Reliability
If higher doses of single agent are used, then treatment efficacy may improve, but toxicity increases
Solution Approach 1:
The patent utilizes parameter changes by administering milciclib at a specific dose (150mg/day) combined with DNA damaging agents at established doses, creating a synergistic effect that achieves superior tumor regression compared to higher doses of single agents. The combination allows each drug to be used at tolerable doses while producing enhanced therapeutic effects through complementary mechanisms of action
Data Source
AI summary
This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, small cell lung carcinoma, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, biliary cancer and melanoma in subjects in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of a DNA damaging agent.